Neuland Laboratories share news, announcements and annual reports
NSE: NEULANDLABBSE: 524558Pharmaceuticals & BiotechnologySmall Cap
Neuland Laboratories Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 1994 on BSE, Oct 2008 on NSE
Last close ₹19,700.00up ₹420.00 (2.18%)BSE ₹19,701.10
Share price at the NSE close on 30 Oct 2026. Previous close ₹19,280.00.
30 Oct: open ₹19,345.00, high ₹19,920.00, low ₹19,025.00
52-week range of traded prices to 30 Oct 2026
₹11,500.00Low, 23 Mar 2026₹24,225.00High, 9 Sep 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹25,275 Cr356th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 50.78
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 13.48
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.17%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 29.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 32.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.10
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 60,08043.6% delivered
Neuland Laboratories share news and announcements
837 announcements, routine notices left out, newest first. Page 14 of 17.
Jan 2016
Oct 2015
Sep 2015
28 Sep · Updates
Aug 2015
Jul 2015
Jun 2015
May 2015
8 May · Dividend
Board of Directors in their meeting held on May 8, 2015 have recommended payment of dividend of 15% at Rs.1.50 per equity share on a face value of Rs.10 each, subject to the approval of members of the company.
Apr 2015
Feb 2015
Jan 2015
9 Jan · Board meeting
Inter-alia to consider and take on record the un-audited financial results of the Company for the quarter ended December 31, 2014.
Dec 2014
Nov 2014
8 Nov · Corporate action
Oct 2014
29 Oct · Board meeting
Board of Directors of the Company, had at its meeting held on October 29, 2014: Allotted 12,22,472 fully paid up Equity Shares of Face Value of Rs. 10/- each, out of the Rights Issue of 12,25,276 Equity shares and the balance has been kept in abeyance.16 Oct · Board meeting
Inter-alia to consider and take on record the un-audited financial results of the Company for the quarter ended September 30, 2014. Further as per the provisions of the Code of Conduct for Prevention of Insider Trading of the Company, the Trading Window for transactions in shares of the Company is closed from October 14, 2014 to October 30, 2014 (both days inclusive), inter alia, for the purpose of announcement of the un-audited Financial Results by the Company.
Sep 2014
Aug 2014
4 Aug · Corporate action
Company has fixed Record Date as August 14, 2014 for the purpose of Rights Issue.1 Aug · Board meeting
Jul 2014
9 Jul · Board meeting
Inter-alia to consider and take on record the un-audited financial results of the Company for the quarter ended June 30, 2014. Further, the Company has informed the Exchange that as per the provisions of the Code of Conduct for Prevention of Insider Trading of the Company, the Trading Window for transactions in shares of the Company is closed from July 17, 2014 to August 5, 2014 (both days inclusive), inter alia, for the purpose of announcement of the un-audited Financial Results by the Company.
Jun 2014
May 2014
14 May · Board meeting
Board of Directors of the Company at its meeting held on May 09, 2014, had appointed Mrs. Bharati Rao as an Additional Director on the Board of the Company effective May 09, 201413 May · Meeting
Register of members and share transfer books of the company will remain closed June 18, 2014 to June 24, 2014 (both days inclusive) for the purpose of Dividend and Annual General Meeting of the Company to be held on June 24, 2014.